KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Work In Process: 2019-2024

Historic Work In Process for Ionis Pharmaceuticals (IONS) over the last 6 years, with Dec 2024 value amounting to $6.7 million.

  • Ionis Pharmaceuticals' Work In Process rose 44.84% to $8.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.7 million, marking a year-over-year increase of 44.84%. This contributed to the annual value of $6.7 million for FY2024, which is 21.95% up from last year.
  • As of FY2024, Ionis Pharmaceuticals' Work In Process stood at $6.7 million, which was up 21.95% from $5.5 million recorded in FY2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Work In Process peaked at $6.7 million during FY2024, and registered a low of $2.1 million during FY2022.
  • In the last 3 years, Ionis Pharmaceuticals' Work In Process had a median value of $5.5 million in 2023 and averaged $4.8 million.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Work In Process crashed by 63.45% in 2022, and later soared by 159.70% in 2023.
  • Over the past 5 years, Ionis Pharmaceuticals' Work In Process (Yearly) stood at $2.3 million in 2020, then spiked by 156.22% to $5.8 million in 2021, then tumbled by 63.45% to $2.1 million in 2022, then surged by 159.70% to $5.5 million in 2023, then increased by 21.95% to $6.7 million in 2024.